Prospective observational study on preoperative algorithm treatment for Borderline Resectable Pancreatic Cancer with positive radiological arterial invasion - Prospective study on preoperative algorithm treatment for BRPC-A

Second Department of Surgery, Wakayama Medical University0 sites50 target enrollmentJune 16, 2020

Overview

Phase: 未知
Intervention: Not specified
Conditions: Borderline Resectable Pancreatic Cancer with positive radiological arterial invasion
Sponsor: Second Department of Surgery, Wakayama Medical University
Enrollment: 50
Status: Recruiting
Last Updated: 2 years ago

No summary available.

Registry

who.int

Start Date

June 16, 2020

End Date

May 31, 2025

Last Updated

2 years ago

Study Type

Observational

Sex

All

Sponsor

Second Department of Surgery, Wakayama Medical University

•1\. Cases with a history of severe drug hypersensitivity or drug allergy 2\. Cases with a history of malignant tumor (\* If there is a recurrence\-free period of 5 years or more, and endoscopically curatively resected intramucosal cancer, curatively resected cervical cancer, and basal cell carcinoma of the skin Or squamous cell carcinoma can be registered) 3\. Cases with active infection 4\. Patients with peripheral sensory neuropathy (Grade 2 or higher) 5\. Cases with a history of interstitial pneumonia or pulmonary fibrosis 6\. Patients with uncontrolled ascites or pleural effusion 7\. Cases receiving atazanavir sulfate 8\. Cases with uncontrolled diabetes 9\. Uncontrollable congestive heart failure, angina, hypertension, arrhythmia 10\. History of neurologically or psychologically significant disease, and cases with complications 11\. Cases with diarrhea (including increased number of stools and watery stools) 12\. Pregnant women, lactating women, and cases of possible pregnancy (will), or women and men who are not willing to contracept during the study period and for a certain period (180 days) after the last administration of the study drug 13\. Patients with active hepatitis B 14\. Regarding UGT1A1\*6 and \*28 gene polymorphisms, have either of them as homozygotes (UGT1A1\*6/\*6, UGT1A1\*28/\*28\) or both as heterozygotes (UGT1A1\*6/\*28\) Case